Dr. Gary Mo received his Ph.D. in Neuroscience from McGill University. He has many years of industrial collaboration and joined the AstraZeneca sponsored PKPD postdoctoral program after his graduation. His current work within the Center for Protein Therapeutics involves the development of a mechanistic model to describe the changes in regulation of granulopoiesis following chemotherapy induced neutropenia. The model will describe the pharmacodynamic mediated disposition of G-CSF and its effect on stimulation of neutrophil production.